

KRYXANA[®] (ribociclib)
200 mg film-coated tablets

Professional Information

Document status: Final

Approval date: 21 July 2022

SCHEDULING STATUS **S4**

1. NAME OF THE MEDICINAL PRODUCT

Kryxana 200 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains ribociclib succinate, equivalent to 200 mg ribociclib.

Excipients with known effect

Each film-coated tablet contains 0.344 mg soya lecithin.

For the full list of excipients, see section 6.1.

Sugar free.

3. PHARMACEUTICAL FORM

Film-coated tablet.

Light greyish violet, unscored, round, curved with bevelled edges (approximate diameter: 11.1 mm), debossed with "RIC" on one side and "NVR" on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Kryxana is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or in combination with fulvestrant, as initial endocrine-based therapy or in women who have received prior endocrine based therapy.

In pre- or perimenopausal women, the endocrine based therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

4.2 Posology and method of administration

Treatment with Kryxana should be initiated by a medical practitioner experienced in the use of anticancer therapies.

Posology

The recommended dose is 600 mg (three 200 mg film-coated tablets) of ribociclib once daily for 21 consecutive days followed by 7 days off treatment, resulting in a complete cycle of 28 days. The treatment should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.

Kryxana should be used together with 2.5 mg letrozole or another aromatase inhibitor or with 500 mg fulvestrant.

When Kryxana is used in combination with an aromatase inhibitor, the aromatase inhibitor should be taken orally once daily continuously throughout the 28-day cycle. Please refer to the Professional Information (PI) of the particular aromatase inhibitor for additional details.

When Kryxana is used in combination with fulvestrant, fulvestrant is administered intramuscularly on days 1, 15 and 29, and once monthly thereafter. Please refer to the Professional Information (PI) of fulvestrant for additional details.

Treatment of pre- and perimenopausal women with the approved Kryxana combinations should also include a LHRH agonist in accordance with local clinical practice.

Kryxana can be taken with or without food (see section 4.5). Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning. If the patient vomits after taking the dose or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.

Dose modifications

Management of severe or intolerable adverse drug reactions (ADRs) may require temporary dose interruption, reduction or discontinuation of Kryxana. If dose reduction is required, the recommended dose reduction guidelines are listed in Table 1.

Table 1 Recommended dose modification guidelines

	Kryxana	
	Dose	Number of 200 mg tablets
Starting dose	600 mg/day	3
First dose reduction	400 mg/day	2
Second dose reduction	200 mg*/day	1
* If further dose reduction below 200 mg/day is required, the treatment should be permanently discontinued.		

Tables 2, 3, 4, 5 and 6 summarise recommendations for dose interruption, reduction or discontinuation of Kryxana in the management of specific ADRs. The clinical judgement of the treating medical practitioner should guide the management plan of each patient based on individual benefit/risk

assessment (see section 4.4).

Complete blood counts (CBC) should be performed before initiating treatment with Kryxana. After initiating treatment CBC should be monitored every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, then as clinically indicated.

Table 2 Dose modification and management – Neutropenia

	Grade 1 or 2* (ANC 1000 /mm ³ – ≤ LLN)	Grade 3* (ANC 500 – < 1000/mm ³)	Grade 3* febrile neutropenia**	Grade 4* (ANC < 500/mm ³)
Neutropenia	No dose adjustment is required	Dose interruption until recovery to grade ≤ 2. Resume Kryxana at the same dose level. If toxicity recurs at grade 3: dose interruption until recovery to grade ≤ 2, then resume Kryxana and reduce by 1 dose level.	Dose interruption until recovery to grade ≤ 2. Resume Kryxana and reduce by 1 dose level	Dose interruption until recovery to grade ≤ 2. Resume Kryxana and reduce by 1 dose level.
* Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events) ** Grade 3 neutropenia with a single fever > 38.3 °C (or above 38 °C for more than one hour and/or concurrent infection) ANC = absolute neutrophil count; LLN = lower limit of normal				

Liver function tests (LFTs) should be performed before initiating treatment with Kryxana. After initiating treatment LFTs should be performed every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, then as clinically indicated. If grade ≥ 2 abnormalities are noted, more frequent monitoring is recommended.

Table 3 Dose modification and management – Hepatobiliary toxicity

	Grade 1* (> ULN – 3 x ULN)	Grade 2* (> 3 to 5 x ULN)	Grade 3* (> 5 to 20 x ULN)	Grade 4* (> 20 x ULN)
AST and/or ALT elevations from baseline**, without increase in total bilirubin above 2 x ULN	No dose adjustment is required.	Baseline grade < 2: Dose interruption until recovery to ≤ baseline grade, then resume Kryxana at same dose level. If grade 2 recurs, resume Kryxana at next lower dose level. Baseline grade = 2: No dose interruption.	Dose interruption of Kryxana until recovery to ≤ baseline grade, then resume at next lower dose level. If grade 3 recurs, discontinue Kryxana.	Discontinue Kryxana.
Combined elevations in AST and/or ALT together with total bilirubin increase, in the absence of cholestasis	If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue Kryxana.			

* Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)

** Baseline = prior to treatment initiation

ULN = upper limit of normal

ECG should be assessed before initiating treatment with Kryxana. After initiating treatment, ECG should be repeated at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated. In case of QTcF prolongation during treatment, more frequent ECG monitoring is recommended.

Table 4 Dose modification and management – QT prolongation

ECGs with QTcF > 480 msec	1. The dose should be interrupted. 2. If QTcF prolongation resolves to < 481 msec, resume treatment at the next lower dose level. 3. If QTcF ≥ 481 msec recurs, interrupt dose until QTcF resolves to < 481 msec and then resume Kryxana at the next lower dose level.
ECGs with QTcF > 500 msec	If QTcF is greater than 500 msec, interrupt Kryxana until QTcF is < 481 msec then resume Kryxana at next lower dose level. If QTcF interval prolongation to greater than 500 msec or greater than 60 msec change from baseline occurs in combination with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious dysrhythmias, permanently discontinue Kryxana.

Table 5 Dose modification and management – ILD/pneumonitis

	Grade 1* (asymptomatic)	Grade 2* (symptomatic)	Grade 3 or 4* (severe)
ILD/pneumonitis	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Dose interruption until recovery to grade ≤ 1, then resume Kryxana at the next lower dose level**.	Discontinue Kryxana
*Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events) ** An individualised benefit-risk assessment should be performed when considering resuming Kryxana ILD = interstitial lung disease			

Table 6 Dose modification and management – Other toxicities*

Other toxicities	Grade 1 or 2**	Grade 3**	Grade 4**
	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Dose interruption until recovery to grade ≤ 1 , then resume Kryxana at the same dose level. If grade 3 recurs, resume Kryxana at the next lower dose level.	Discontinue Kryxana.
* Excluding neutropenia, hepatotoxicity, QT interval prolongation and ILD/pneumonitis.			
** Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)			

Refer to the PI for the co-administered aromatase inhibitor, fulvestrant or LHRH agonist for dose modification guidelines and other relevant safety information in the event of toxicity.

Dose modification for use of Kryxana with strong CYP3A4 inhibitors

Concomitant use of strong CYP3A4 inhibitors should be avoided and an alternative concomitant medicine with less potential to inhibit CYP3A4 inhibition should be considered. (See 4.3 and 4.4). If patients must be given a strong CYP3A4 inhibitor concomitantly with ribociclib, the Kryxana dose should be reduced to 400 mg once daily (see section 4.5).

In patients who have had their dose reduced to 400 mg ribociclib daily and in whom initiation of co-administration of a strong CYP3A4 inhibitor cannot be avoided, the dose should be further reduced to 200 mg.

In patients who have had their dose reduced to 200 mg ribociclib daily and in whom initiation of co-administration of a strong CYP3A4 inhibitor cannot be avoided, Kryxana treatment should be interrupted.

Due to inter-patient variability, the recommended dose adjustments may not be optimal in all patients, therefore close monitoring of signs of toxicity is recommended. If the strong inhibitor is discontinued, the Kryxana dose should be changed to the dose used prior to the initiation of the strong CYP3A4 inhibitor after at least 5 half-lives of the strong CYP3A4 inhibitor (see sections 4.4, 4.5 and 5.2).

Special populations

Renal impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2). A starting dose of 200 mg is recommended in patients with severe renal impairment (see section 5.2). Caution should be used in patients with severe renal impairment with close monitoring of signs of toxicity (see section 5.2).

Hepatic impairment

Based on a pharmacokinetic study in healthy subjects and non-cancer subjects with impaired hepatic function, no dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). Patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) can have increased (less than 2-fold) exposure to ribociclib and the starting dose of 400 mg Kryxana once daily is recommended. Ribociclib has not been studied in breast cancer patients with moderate and severe hepatic impairment (see section 5.2).

Paediatric population

The safety and efficacy of Kryxana in children and adolescents aged below 18 years have not been established. No data are available.

Elderly

No dose adjustment is required in patients over 65 years of age (see section 5.2).

Method of administration

Kryxana should be taken orally once daily with or without food. The tablets should be swallowed whole and should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked or otherwise not intact.

4.3 Contraindications

Hypersensitivity to the active substance or to peanut, soya or any of the excipients listed in section 6.1.

Concomitant use of Kryxana with medicines that have a known potential to prolong the QTcF interval to ≥ 500 ms, or ≥ 60 ms from the pre-treatment QTcF, increasing the risk to develop serious dysrhythmias (e.g. tamoxifen, moxifloxacin).

Congenital long QT syndrome.

Concomitant use of Kryxana with strong CYP3A inhibitors (e.g. ritonavir/lopinovir, itraconazole).

Concomitant use of Kryxana with CYP3A substrates with a narrow therapeutic index (e.g. midazolam, fentanyl).

Concomitant use with strong CYP3A4 inducers (e.g. rifampicin, phenytoin).

Pregnancy and lactation.

Difficult to control/unstable severe cardiac conditions including dysrhythmias, congestive cardiac failure, recent myocardial infarction and unstable angina pectoris.

4.4 Special warnings and precautions for use

Critical visceral disease

The efficacy and safety of ribociclib have not been studied in patients with critical visceral disease.

Neutropenia

Based on the severity of the neutropenia, treatment with Kryxana may have to be interrupted, reduced or discontinued as described in Table 2 (see sections 4.2 and 4.8).

Hepatobiliary toxicity

Liver function tests should be performed before initiating treatment with Kryxana. After initiating treatment, liver function should be monitored (see sections 4.2 and 4.8).

Based on the severity of the transaminase elevations, treatment with Kryxana may have to be interrupted, reduced or discontinued as described in Table 3 (see sections 4.2 and 4.8).

Recommendations for patients who have elevated AST/ALT grade ≥ 3 at baseline have not been established.

QT interval prolongation

In study E2301 (MONALEESA-7), a QTcF interval increase > 60 msec from baseline was observed in 14/87 (16.1%) patients receiving Kryxana plus tamoxifen and in 18/245 (7.3%) patients receiving Kryxana plus a non-steroidal aromatase inhibitor (NSAI). Kryxana is not recommended to be used in combination with tamoxifen (see sections 4.8 and 5.1) (See Interactions with other medicines and contraindications).

ECG should be assessed before initiating treatment. Treatment with Kryxana should be initiated only in patients with QTcF values less than 450 msec. ECG should be repeated at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated (see sections 4.2 and 4.8).

Appropriate monitoring of serum electrolytes (including potassium, calcium, phosphorus and magnesium) should be performed before initiating treatment, at the beginning of the first 6 cycles and

then as clinically indicated. Any abnormality should be corrected before initiating treatment with Kryxana and during treatment with Kryxana.

The use of Kryxana should be avoided in patients who already have or who are at significant risk of developing QTc prolongation. (See Interactions with other medicines and contraindications). This includes patients:

- with long QT syndrome;
- with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias;
- with electrolyte abnormalities.

The use of Kryxana with medicines known to prolong QTc interval and/or strong CYP3A4 inhibitors should be avoided as this may lead to clinically meaningful prolongation of the QTcF interval (see sections 4.2, 4.5 and 5.1) (See Interactions with other medicines and contraindications). If treatment with a strong CYP3A4 inhibitor cannot be avoided, the dose should be reduced to 400 mg once daily (see sections 4.2 and 4.5).

Based on the observed QT prolongation during treatment, treatment with Kryxana may have to be interrupted, reduced or discontinued as described in Table 4 (see sections 4.2, 4.8 and 5.2).

Interstitial lung disease/pneumonitis

ILD/pneumonitis has been reported with CDK4/6 inhibitors including Kryxana. In the 3 phase III clinical studies (MONALEESA-2 [A2301], MONALEESA-7 [E2301-NSAI] and MONALEESA-3 [F2301]), ILD (any grade 0.3%, including 0.1% grade 3) was reported in the Kryxana treated group, with no cases in the placebo treated group. Pneumonitis was reported in both the Kryxana and the placebo treated groups (any grade 0.4 %, with no grade 3 or 4 in either treatment group).

Based on the severity of the ILD/pneumonitis, which may be fatal, Kryxana may require dose interruption, reduction or discontinuation as described in Table 5 (see section 4.2).

Patients should be monitored for pulmonary symptoms indicative of ILD/pneumonitis which may include hypoxia, cough and dyspnoea and dose modifications should be managed in accordance with Table 5 (see section 4.2).

Severe cutaneous reactions

Toxic epidermal necrolysis (TEN) has been reported with Kryxana treatment. If signs and symptoms suggestive of severe cutaneous reactions (e.g. progressive widespread skin rash often with blisters or mucosal lesions) appear, Kryxana should be immediately and permanently discontinued.

CYP3A4 substrates

Ribociclib is a strong CYP3A4 inhibitor at the 600 mg dose and a moderate CYP3A4 inhibitor at the 400 mg dose. Thus, ribociclib may interact with medicines which are metabolised via CYP3A4, which may lead to increased serum concentrations of CYP3A4 substrates (see section 4.5). Caution is recommended in case of concomitant use with sensitive CYP3A4 substrates with a narrow therapeutic index and the PIs of the other medicines should be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors (See Interactions with other medicines and contraindications).

Women of childbearing potential

Women of childbearing potential should be advised to use an effective method of contraception while taking Kryxana and for at least 21 days after the last dose (see section 4.6).

Soya lecithin

Kryxana contains soya lecithin. Patients who are hypersensitive to peanut or soya should not take Kryxana (see section 4.3).

4.5 Interaction with other medicines and other forms of interaction

Substances that may increase ribociclib plasma concentrations

Ribociclib is primarily metabolised by CYP3A4. Therefore, medicines that can influence CYP3A4 enzyme activity may alter the pharmacokinetics of ribociclib. Co-administration of the strong CYP3A4 inhibitor ritonavir (100 mg twice daily for 14 days) with a single 400 mg dose of ribociclib increased ribociclib exposure (AUC_{inf}) and the peak concentration (C_{max}) in healthy subjects 3.2 and 1.7-fold, respectively, relative to a single 400 mg ribociclib dose given alone. C_{max} and AUC_{last} for LEQ803 (a prominent metabolite of ribociclib accounting for less than 10 % of parent exposure) decreased by 96 % and 98 %, respectively.

The concomitant use of strong CYP3A4 inhibitors including, but not limited to, the following must be avoided: clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir, ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil and voriconazole (see section 4.4) (See Special warnings and precautions for use and contraindications). Alternative concomitant medicines with less potential to inhibit CYP3A4 should be considered and patients should be monitored for ribociclib-related AEs (see sections 4.2, 4.4 and 5.2).

If co-administration of Kryxana with a strong CYP3A4 inhibitor cannot be avoided, the dose of Kryxana should be reduced as described in section 4.2. (See Special warnings and precautions for use and contraindications). However, there are no clinical data with these dose adjustments. Due to inter-patient variability, the recommended dose adjustments may not be optimal in all patients, therefore close monitoring for ribociclib-related AEs is recommended. In the event of ribociclib-related

toxicity, the dose should be modified or treatment should be interrupted until toxicity is resolved (see sections 4.2 and 5.2). If the strong CYP3A4 inhibitor is discontinued, and after at least 5 half-lives of the CYP3A4 inhibitor (refer to the PI of the CYP3A4 inhibitor in question), Kryxana should be resumed at the same dose used prior to the initiation of the strong CYP3A4 inhibitor.

Physiologically-based pharmacokinetic simulations suggested that at a 600 mg dose of ribociclib, a moderate CYP3A4 inhibitor (erythromycin) may increase ribociclib steady-state C_{max} and AUC 1.2 and 1.3-fold, respectively. For patients who had their ribociclib dose reduced to 400 mg once daily, the increase of the steady-state C_{max} and AUC was estimated to be 1.4- and 2.1-fold, respectively. The effect at the 200 mg once-daily dose was predicted to be a 1.7- and 2.8-fold increase, respectively. No dose adjustments of ribociclib are required at initiation of treatment with mild or moderate CYP3A4 inhibitors. However, monitoring of ribociclib-related AEs is recommended.

Patients should be instructed to avoid grapefruit or grapefruit juice. These are known to inhibit cytochrome CYP3A4 enzymes and may increase the exposure to ribociclib.

Substances that may decrease ribociclib plasma concentrations

Co-administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 14 days) with a single 600 mg dose of ribociclib decreased the ribociclib AUC_{inf} and C_{max} by 89 % and 81 %, respectively, relative to a single 600 mg ribociclib dose given alone in healthy subjects. LEQ803 C_{max} increased 1.7-fold and AUC_{inf} decreased by 27 %, respectively. The concomitant use of strong CYP3A4 inducers may therefore lead to decreased exposure and consequently a risk for lack of efficacy. The concomitant use of strong CYP3A4 inducers should be avoided, including, but not limited to, phenytoin, rifampicin, carbamazepine and St John's Wort (*Hypericum perforatum*). An alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered (See Special warnings and precautions for use and contraindications).

The effect of a moderate CYP3A4 inducer on ribociclib exposure has not been studied.

Physiologically-based pharmacokinetic simulations suggested that a moderate CYP3A4 inducer (efavirenz) may decrease steady-state ribociclib $C_{\max}$ and AUC by 51 % and 70 %, respectively. The concomitant use of moderate CYP3A4 inducers may therefore lead to decreased exposure and consequently a risk for impaired efficacy, in particular in patients treated with ribociclib at 400 mg or 200 mg once daily.

Substances that may have plasma concentrations altered by Kryxana

Ribociclib is a moderate to strong CYP3A4 inhibitor and may interact with medicinal substrates that are metabolised via CYP3A4, which can lead to increased serum concentrations of the concomitantly used medicine.

Co-administration of midazolam (CYP3A4 substrate) with multiple doses of Kryxana (400 mg) increased the midazolam exposure by 280 % (3.80-fold) in healthy subjects, compared with administration of midazolam alone. Simulations using physiologically-based pharmacokinetic models suggested that Kryxana given at the clinically relevant dose of 600 mg is expected to increase the midazolam AUC by 5.2-fold. Therefore, when ribociclib is co-administered with other medicines the PI of the other medicinal product must be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors. (See Special warnings and precautions for use and contraindications).

Caution is recommended in case of concomitant use with sensitive CYP3A4 substrates with a narrow therapeutic index (see section 4.4). The dose of a sensitive CYP3A4 substrate with a narrow therapeutic index, including but not limited to alfentanil, ciclosporin, everolimus, fentanyl, sirolimus and tacrolimus, may need to be reduced as ribociclib can increase their exposure. (See Special warnings and precautions for use and contraindications).

Concomitant administration of ribociclib at the 600 mg dose with the following CYP3A4 substrates should be avoided: alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine,

dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, midazolam, triazolam. (See Special warnings and precautions for use and contraindications).

Co-administration of caffeine (CYP1A2 substrate) with multiple doses of Kryxana (400 mg) increased the caffeine exposure by 20 % (1.20-fold) in healthy subjects, compared with administration of caffeine alone. At the clinically relevant dose of 600 mg, simulations using PBPK models predicted only weak inhibitory effects of ribociclib on CYP1A2 substrates (< 2-fold increase in AUC).

Substances that are substrates of transporters

In vitro evaluations indicated that ribociclib has a potential to inhibit the activities of drug transporters P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP. Caution and monitoring for toxicity are advised during concomitant treatment with sensitive substrates of these transporters which exhibit a narrow therapeutic index, including but not limited to digoxin, pitavastatin, pravastatin, rosuvastatin and metformin.

Drug-food interactions

Kryxana can be administered with or without food (see sections 4.2 and 5.2).

Medicines that elevate gastric pH

Ribociclib exhibits high solubility at or below pH 4.5 and in bio-relevant media (at pH 5.0 and 6.5).

Co-administration of ribociclib with medicines that elevate the gastric pH was not evaluated in a clinical study; however, altered ribociclib absorption was not observed in population pharmacokinetic and non-compartmental pharmacokinetic analyses.

Interaction between ribociclib and letrozole

Data from a clinical study in patients with breast cancer and population pharmacokinetic analysis indicated no interaction between ribociclib and letrozole following co-administration of these medicines.

Interaction between ribociclib and anastrozole

Data from a clinical study in patients with breast cancer indicated no clinically relevant interaction between ribociclib and anastrozole following co-administration of these medicines.

Interaction between ribociclib and fulvestrant

Data from a clinical study in patients with breast cancer indicated no clinically relevant effects of fulvestrant on ribociclib exposure following co-administration of these medicines.

Interaction between ribociclib and tamoxifen

Data from a clinical study in patients with breast cancer indicated that tamoxifen exposure was increased approximately 2-fold following co-administration of ribociclib and tamoxifen.

Interaction between ribociclib and oral contraceptives

Interaction studies between ribociclib and oral contraceptives have not been conducted (see section 4.6).

Anticipated interactions

Antidysrhythmic medicines and other medicines that may prolong the QT interval

Co-administration of Kryxana with medicines with a known potential to prolong the QT interval such as antidysrhythmic medicines (including, but not limited to, amiodarone, disopyramide, procainamide, quinidine and sotalol), and other medicines that are known to prolong the QT interval (including, but

not limited to, chloroquine, halofantrine, clarithromycin, ciprofloxacin, levofloxacin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide and intravenous ondansetron) should be avoided (see section 4.4) (See Special warnings and precautions for use and contraindications).

Kryxana is also not recommended to be used in combination with tamoxifen (see sections 4.1, 4.4 and 5.1).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Pregnancy status should be verified prior to starting treatment with Kryxana.

Women of childbearing potential who are receiving Kryxana should use effective contraception (e.g. double-barrier contraception) during therapy and for at least 21 days after stopping treatment with Kryxana.

Pregnancy

Kryxana is teratogenic and contraindicated in pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women. Based on findings in animals, ribociclib can cause foetal harm when administered to a pregnant woman (see section 5.3). Kryxana is contraindicated during pregnancy and in women of childbearing potential not using contraception. (See Special warnings and precautions for use and contraindications)

Breast-feeding

It is not known if ribociclib is present in human milk. There are no data on the effects of ribociclib on the breast-fed infant or the effects of ribociclib on milk production. Ribociclib and its metabolites readily

passed into the milk of lactating rats. Mothers on treatment with Kryxana should not breast-feed their infants (See Special warnings and precautions for use and contraindications). Mothers receiving Kryxana should not breast-feed for at least 21 days after the last dose.

Fertility

There are no clinical data available regarding effects of ribociclib on fertility. Based on animal studies, ribociclib may impair fertility in males of reproductive potential (see section 5.3).

4.7 Effects on ability to drive and use machines

Kryxana may have an influence on the ability of patients to drive and use machines. Patients should be advised to be cautious when driving or using machines in case they experience fatigue, dizziness or vertigo during treatment with Kryxana (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

The most common ADRs and the most common grade 3/4 ADRs (reported at a frequency $\geq 20\%$ and $\geq 2\%$, respectively) in the pooled dataset for which the frequency for Kryxana plus any combination exceeds the frequency for placebo plus any combination were infections, neutropenia, leukopenia, headache, cough, nausea, fatigue, diarrhoea, vomiting, constipation, alopecia and rash, and infections, neutropenia, leukopenia, anaemia, abnormal liver function tests, lymphopenia, hypophosphataemia and vomiting respectively.

Dose reduction due to adverse events, regardless of causality, occurred in 37.3 % of patients receiving Kryxana in the phase III clinical studies regardless of the combination and permanent discontinuation was reported in 7.0 % of patients receiving Kryxana and any combination in the phase III clinical studies.

Tabulated list of adverse reactions

The overall safety evaluation of Kryxana is based on the pooled dataset from 1,065 patients who received Kryxana in combination with endocrine therapy (N = 582 in combination with an aromatase inhibitor and N = 483 in combination with fulvestrant) and who were included in the randomised, double blind, placebo-controlled phase III clinical studies (MONALEESA 2, MONALEESA 7 NSAI subgroup and MONALEESA 3) in HR positive, HER2 negative advanced or metastatic breast cancer. Additional ADRs were identified post-marketing.

The median duration of exposure to Kryxana treatment across the pooled phase III studies dataset was 21.7 months, with 61.7 % patients exposed $\geq$ 12 months.

Adverse drug reactions from the phase III clinical studies (Table 7) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($\geq$ 1/10); common ($\geq$ 1/100 to $<$ 1/10); uncommon ($\geq$ 1/1,000 to $<$ 1/100); rare ($\geq$ 1/10,000 to $<$ 1/1,000); very rare ($<$ 1/10,000); and not known (cannot be estimated from the available data).

Table 7 Adverse drug reactions observed in the three phase III clinical studies

Adverse drug reactions	Kryxana N = 1065 n (%) All Grades	Kryxana N = 1065 n (%) Grades 3/4	Frequency category All Grades
Infections and infestations			
Infections ¹	434 (40.8)	41 (3.8)	Very common

Blood and lymphatic system disorders			
Neutropenia	785 (73.7)	624 (58.6)	Very common
Leukopenia	314 (29.5)	165 (15.5)	Very common
Anaemia	200 (18.8)	30 (2.8)	Very common
Lymphopenia	95 (8.9)	56 (5.3)	Common
Thrombocytopenia	95 (8.9)	8 (0.8)	Common
Febrile neutropenia	15 (1.4)	15 (1.4)	Common
Eye disorders			
Lacrimation increased	59 (5.5)	0	Common
Dry eye	54 (5.1)	0	Common
Metabolism and nutrition disorders			
Decreased appetite	163 (15.3)	6 (0.6)	Very common
Hypocalcaemia	45 (4.2)	11 (1.0)	Common
Hypokalaemia	33 (3.1)	12 (1.1)	Common
Hypophosphataemia	34 (3.2)	22 (2.1)	Common
Nervous system disorders			
Headache	253 (23.8)	5 (0.5)	Very common
Dizziness	125 (11.7)	1 (0.1)	Very common
Vertigo	46 (4.3)	1 (0.1)	Common
Cardiac disorders			
Syncope	19 (1.8)	12 (1.1)	Common
Respiratory, thoracic and mediastinal disorders			
Dyspnoea	132 (12.4)	15 (1.4)	Very common
Cough	218 (20.5)	0	Very common
Musculoskeletal and connective tissue disorders			
Back pain	211 (19.8)	20 (1.9)	Very common
Gastrointestinal disorders			
Nausea	475 (44.6)	15 (1.4)	Very common
Diarrhoea	317 (29.8)	16 (1.5)	Very common
Vomiting	284 (26.7)	21 (2.0)	Very common
Constipation	253 (23.8)	8 (0.8)	Very common

Stomatitis	122 (11.5)	3 (0.3)	Very common
Abdominal pain ²	182 (17.1)	14 (1.3)	Very common
Dysgeusia	71 (6.7)	1 (0.1)	Common
Dyspepsia	88 (8.3)	1 (0.1)	Common
Hepatobiliary disorders			
Hepatotoxicity ³	19 (1.8)	15 (1.4)	Common
Skin and subcutaneous tissue disorders			
Alopecia	256 (24.0)	0	Very common
Rash ⁴	227 (21.3)	10 (0.9)	Very common
Pruritus	177 (16.6)	3 (0.3)	Very common
Erythema	43 (4.0)	2 (0.2)	Common
Dry skin	88 (8.3)	0	Common
Vitiligo	16 (1.5)	0	Common
General disorders and administration site conditions			
Fatigue	348 (32.7)	20 (1.9)	Very common
Peripheral oedema	147 (13.8)	1 (0.1)	Very common
Asthenia	145 (13.6)	7 (0.7)	Very common
Pyrexia	139 (13.1)	4 (0.4)	Very common
Dry mouth	74 (6.9)	1 (0.1)	Common
Oropharyngeal pain	67 (6.3)	0	Common
Investigations			
Abnormal liver function tests ⁵	184 (17.3)	93 (8.7)	Very common
Blood creatinine increased	67 (6.3)	4 (0.4)	Common
Electrocardiogram QT prolonged	69 (6.5)	13 (1.2)	Common

¹ Infections: Urinary tract infections; respiratory tract infections; gastroenteritis; sepsis (< 1 %).

² Abdominal pain: Abdominal pain, abdominal pain upper.

³ Hepatotoxicity: hepatocellular injury, drug induced liver injury, hepatotoxicity, hepatic failure, autoimmune hepatitis (single case).

⁴ Rash: rash, rash maculopapular, rash pruritic.

⁵ Abnormal liver function tests: ALT increased, AST increased, blood bilirubin increased.

Post marketing data

The following ADR is derived from post-marketing experience with Kryxana via spontaneous case reports and literature cases. As this reaction is reported voluntarily from a population of uncertain size, it is not possible to reliably estimate its frequency which is therefore categorized as not known.

Table 8 Adverse drug reactions derived from spontaneous reports and literature (frequency not known)

Skin and subcutaneous tissue disorders	
	Toxic epidermal necrolysis (TEN)

Description of selected adverse drug reactions

Neutropenia

Neutropenia was the most frequently reported adverse drug reaction (73.7 %) and a grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 58.6 % of patients receiving Kryxana plus any combination in the phase III studies.

Among the patients who had grade 2, 3 or 4 neutropenia, the median time to onset was 16 days, for those patients who had an event. The median time to resolution of grade ≥ 3 (to normalisation or grade < 3) was 12 days in the Kryxana plus any combination arms following treatment interruption and/or reduction and/or discontinuation. Febrile neutropenia was reported in about 1.4 % of patients exposed to Kryxana in the phase III studies. Patients should be instructed to report any fever promptly.

Based on its severity, neutropenia was managed by laboratory monitoring, dose interruption and/or dose modification. Treatment discontinuation due to neutropenia was low (0.8 %) (See sections 4.2 and 4.4).

Hepatobiliary toxicity

In the phase III clinical studies, hepatobiliary toxicity events occurred in a higher proportion of patients in the Kryxana plus any combination arms compared with the placebo plus any combination arms (23.2 % versus 16.5 %, respectively), with more grade 3/4 adverse events reported in the patients treated with Kryxana plus any combination (11.4 % versus 5.4 %, respectively). Increases in transaminases were observed. Grade 3 or 4 increases in ALT (9.7 % versus 1.5 %) and AST (6.7 % versus 2.1 %) were reported in the Kryxana and placebo arms, respectively. Concurrent elevations in ALT or AST greater than three times the upper limit of normal and total bilirubin greater than two times the upper limit of normal, with normal alkaline phosphatase, in the absence of cholestasis, occurred in 6 patients, (4 patients, whose levels recovered to normal within 154 days and 2 patients whose levels recovered to normal in 121 and 532 days, respectively, after discontinuation of Kryxana).

Dose interruptions and/or adjustments due to hepatobiliary toxicity events were reported in 10.4 % of Kryxana plus any combination treated patients, primarily due to ALT increased (6.9 %) and/or AST increased (6.1 %). Discontinuation of treatment with Kryxana plus any combination due to abnormal liver function tests or hepatotoxicity occurred in 2.3 % and 0.4 % of patients respectively (see sections 4.2 and 4.4).

In the phase III clinical studies, 83.2 % (89/107) of grade 3 or 4 ALT or AST elevation events occurred within the first 6 months of treatment. Among the patients who had grade 3 or 4 ALT/AST elevation, the median time to onset was 85 days for the Kryxana plus any combination arms. The median time to resolution (to normalisation or grade $\leq$ 2) was 22 days in the Kryxana plus any combination arms.

QT prolongation

In study E2301 (MONALEESA 7), the observed mean QTcF increase from baseline was approximately 10 msec higher in the tamoxifen plus placebo subgroup compared with the NSAID plus placebo subgroup,

suggesting that tamoxifen alone had a QTcF prolongation effect which can contribute to the QTcF values observed in the Kryxana plus tamoxifen group. In the placebo arm, a QTcF interval increase of > 60 msec from baseline occurred in 6/90 (6.7 %) patients receiving tamoxifen and in no patients receiving a NSAID (see section 5.2). A QTcF interval increase of > 60 msec from baseline was observed in 14/87 (16.1 %) patients receiving Kryxana plus tamoxifen and in 18/245 (7.3 %) patients receiving Kryxana plus a NSAID. Kryxana is not recommended to be used in combination with tamoxifen (see section 5.1).

In the phase III clinical studies 8.4 % of patients in the Kryxana plus aromatase inhibitor or fulvestrant arms and 3.2 % in the placebo plus aromatase inhibitor or fulvestrant arms had at least one event of QT interval prolongation (including ECG QT prolonged and syncope). Review of ECG data showed 14 patients (1.3 %) had >500 msec post-baseline QTcF value, and 59 patients (5.6 %) had a > 60 msec increase from baseline in QTcF intervals. There were no reported cases of torsade de pointes. Dose interruptions/adjustments were reported in 2.3 % of Kryxana plus aromatase inhibitor or fulvestrant treated patients due to electrocardiogram QT prolonged and syncope.

The analysis of ECG data showed 52 patients (4.9 %) and 11 patients (1.4 %) with at least one > 480 msec post-baseline QTcF for the Kryxana plus aromatase inhibitor or fulvestrant arms and the placebo plus aromatase inhibitor or fulvestrant arms, respectively. Amongst the patients who had QTcF prolongation > 480 msec, the median time to onset was 15 days regardless of the combination and these changes were reversible with dose interruption and/or dose reduction (see sections 4.2, 4.4 and 5.2) (See 4.2, 4.4 and 5.2).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions allows continued monitoring of the benefit/risk balance of Kryxana. Healthcare professionals are asked to report any suspected adverse reactions via patientsafety.sacg@novartis.com and via the “6.04 Adverse Drug Reaction Reporting Form” found online under SAHPRA’s publications: <https://www.sahpra.org.za/Publications/Index/8>.

4.9 Overdose

There is only limited experience with reported cases of overdosage with Kryxana. In the event of an overdose, symptoms such as nausea and vomiting may occur. In addition, hepatobiliary and haematological (e.g. neutropenia, thrombocytopenia) toxicity and possible QTc prolongation may occur. Symptomatic and supportive care should be initiated in all cases of overdosage as necessary.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE42

Mechanism of action

Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signalling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).

In vitro, ribociclib decreased pRb phosphorylation, leading to arrest in the G1 phase of the cell cycle, and reduced cell proliferation in breast cancer cell lines. *In vivo*, treatment with single-agent ribociclib led to tumour regressions which correlated with inhibition of pRb phosphorylation.

In vivo studies demonstrated that combinations of ribociclib and antioestrogens (i.e. letrozole) resulted in tumour growth inhibition with sustained tumour regression and delayed tumour regrowth after stopping dosing compared to each substance alone. An *in vivo* study demonstrated that the combination of ribociclib with fulvestrant resulted in complete tumour growth inhibition.

Ribociclib is more efficacious in ER+ breast cancer cell lines than in the ER- ones. Intact pRb is required for ribociclib activity.

Cardiac electrophysiology

A pharmacokinetic-pharmacodynamic analysis included a total of 997 patients treated with ribociclib at doses ranging from 50 to 1200 mg. The analysis suggested that ribociclib causes concentration-dependent increases in the QTc interval. The estimated QTcF mean change from baseline for 600 mg Kryxana in combination with NSAID or fulvestrant was 22.0 msec (90 % CI: 20.56, 23.44) and 23.7 msec (90 % CI: 22.31, 25.08), respectively at the geometric mean C_{max} at steady-state compared to 34.7 msec (90 % CI: 31.64, 37.78) in combination with tamoxifen (see section 4.4).

Clinical efficacy and safety

Study CLEE011A2301 (MONALEESA-2)

Kryxana was evaluated in a randomised, double-blind, placebo-controlled, multicentre phase III clinical study in the treatment of postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease in combination with letrozole versus letrozole alone.

A total of 668 patients were randomised in a 1:1 ratio to receive either Kryxana 600 mg and letrozole (n = 334) or placebo and letrozole (n = 334), stratified according to the presence of liver and/or lung metastases (Yes [n = 292 (44 %)] versus No [n = 376 (56 %)]). Demographics and baseline disease characteristics were balanced and comparable between study arms. Kryxana was given orally at a dose of 600 mg daily for 21 consecutive days followed by 7 days off treatment in combination with letrozole 2.5 mg once daily for 28 days. Patients were not allowed to cross over from placebo to Kryxana during the study or after progression of disease.

Patients enrolled in this study had a median age of 62 years (range 23 to 91). 44.2 % patients were older than 65 years, including 69 patients older than 75 years. The patients included were Caucasian (82.2 %), Asian (7.6 %), and Black (2.5 %). All patients had an ECOG performance status of 0 or 1. In

the Kryxana arm 43.7 % of patients had received chemotherapy in the neoadjuvant or adjuvant setting and 52.4 % had received antihormonal therapy in the neoadjuvant or adjuvant setting prior to study entry. 34.1 % of patients were *de novo*. 20.7 % of patients had bone-only disease and 59.0 % of patients had visceral disease. Patients with prior (neo) adjuvant therapy with anastrozole or letrozole must have completed this therapy at least 12 months before study randomisation.

The primary endpoint for the study was met at the planned interim analysis conducted after observing 80 % of targeted progression-free survival (PFS) events using Response Evaluation Criteria in Solid Tumours (RECIST v1.1), based on the investigator assessment in the full population (all randomised patients), and confirmed by a blinded independent central radiological assessment.

The efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kryxana plus letrozole compared to patients receiving placebo plus letrozole in the full analysis set (hazard ratio of 0.556, 95 % CI: 0.429, 0.720, one sided stratified log-rank test p-value 0.00000329) with clinically meaningful treatment effect.

The global health status/QoL data showed no relevant difference between the Kryxana plus letrozole arm and the placebo plus letrozole arm.

A more mature update of efficacy data (02 January 2017 cut-off) is provided in Tables 9 and 10.


Median PFS was 25.3 months (95 % CI: 23.0, 30.3) for ribociclib plus letrozole treated patients and 16.0 months (95 % CI: 13.4, 18.2) for patients receiving placebo plus letrozole. 54.7 % of patients receiving ribociclib plus letrozole were estimated to be progression-free at 24 months compared with 35.9 % in the placebo plus letrozole arm.

There was no statistically significant difference in overall survival (OS) between the Kryxana plus letrozole arm and the placebo plus letrozole arm (HR 0.746 [95 % CI: 0.517, 1.078]). OS data remain immature.

Table 9 MONALEESA-2 - Efficacy results (PFS) based on investigator radiological assessment (02 January 2017 cut-off)

	Updated analysis (02 January 2017 cut-off)	
	Kryxana plus letrozole N = 334	Placebo plus letrozole N = 334
Progression-free survival		
Median PFS [months] (95% CI)	25.3 (23.0-30.3)	16.0 (13.4-18.2)
Hazard ratio (95 % CI)	0.568 (0.457-0.704)	
p-value ^a	9.63×10 ⁻⁸	
CI=confidence interval; N=number of patients; ^a p-value is obtained from the one-sided stratified log-rank test.		

Figure 1 MONALEESA-2 - Kaplan-Meier plot of PFS based on investigator assessment 02 January 2017 cut-off)



Number of patients still at risk																		
Time	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34
Ribociclib	334	294	277	257	240	227	207	196	188	176	164	132	97	46	17	11	1	0
Placebo	334	279	265	239	219	196	179	156	138	124	110	93	63	34	10	7	2	0

A series of pre-specified subgroup PFS analyses was performed based on prognostic factors and baseline characteristics to investigate the internal consistency of treatment effect. A reduction in the risk of disease progression or death in favour of the Kryxana plus letrozole arm was observed in all individual patient subgroups of age, race, prior adjuvant or neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease. This was evident for patients with liver and/or lung metastases (HR of 0.561 [95 % CI: 0.424, 0.743], median progression-free survival [mPFS] 24.8 months for Kryxana plus letrozole versus 13.4 months for letrozole alone), or without liver and/or lung metastases (HR of 0.597 [95% CI: 0.426, 0.837], mPFS 27.6 months versus 18.2 months).

Updated results for overall response and clinical benefit rates are displayed in Table 10.

Table 10 MONALEESA-2 - Efficacy results (ORR, CBR) based on investigator assessment (02 January 2017 cut-off)

Analysis	Kryxana + letrozole (%, 95 % CI)	Placebo + letrozole (%, 95 % CI)	p-value ^c
Full analysis set	N = 334	N = 334	
Overall response rate^a	42.5 (37.2, 47.8)	28.7 (23.9, 33.6)	9.18×10^{-5}
Clinical benefit rate^b	79.9 (75.6, 84.2)	73.1 (68.3, 77.8)	0.018
Patients with measurable disease	N = 257	N = 245	
Overall response rate^a	54.5 (48.4, 60.6)	38.8 (32.7, 44.9)	2.54×10^{-4}
Clinical benefit rate^b	80.2 (75.3, 85.0)	71.8 (66.2, 77.5)	0.018
^a ORR: Overall response rate = proportion of patients with complete response + partial response ^b CBR: Clinical benefit rate = proportion of patients with complete response + partial response (+ stable disease or non-complete response/Non-progressive disease ≥ 24 weeks) ^c p-values are obtained from one-sided Cochran-Mantel-Haenszel chi-square test			

Study CLEE011E2301 (MONALEESA-7)

Kryxana was evaluated in a randomised, double-blind, placebo-controlled, multicentre phase III clinical

study in the treatment of pre- and perimenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with a NSAI or tamoxifen plus goserelin versus placebo in combination with a NSAI or tamoxifen plus goserelin. Patients in MONALEESA-7 had not received prior endocrine treatment in the advanced breast cancer setting.

A total of 672 patients were randomised in a 1:1 ratio to receive either Kryxana 600 mg plus NSAI/tamoxifen plus goserelin (n = 335) or placebo plus NSAI/tamoxifen plus goserelin (n = 337), stratified according to: the presence of liver and/or lung metastases (Yes [n = 344 (51.2 %)] versus No [n = 328 (48.8 %)]), prior chemotherapy for advanced disease (Yes [n = 120 (17.9 %)] versus No [n = 552 (82.1 %)]), and endocrine combination partner (NSAI and goserelin [n = 493 (73.4 %)] versus tamoxifen and goserelin [n = 179 (26.6 %)]). Demographics and baseline disease characteristics were balanced and comparable between study arms. Kryxana was given orally at a dose of 600 mg daily for 21 consecutive days followed by 7 days off treatment in combination with NSAI (letrozole 2.5 mg or anastrozole 1 mg) or tamoxifen (20 mg) orally once daily for 28 days, and goserelin (3.6 mg) subcutaneously every 28 days, until disease progression or unacceptable toxicity. Patients were not allowed to cross over from placebo to Kryxana during the study or after disease progression. Switching the endocrine combination partners was also not permitted.


Patients enrolled in this study had a median age of 44 years (range 25 to 58) and 27.7 % of patients were younger than 40 years old. The majority of patients included were Caucasian (57.7%), Asian (29.5 %) or Black (2.8 %) and nearly all patients (99.0 %) had a baseline ECOG performance status of 0 or 1. Prior to study entry, of these 672 patients, 14 % of patients had received prior chemotherapy for metastatic disease, 32.6 % of patients had received chemotherapy in the adjuvant and 18.0 % in the neoadjuvant setting; 39.6 % had received endocrine therapy in the adjuvant setting and 0.7 % in the neoadjuvant setting. In study E2301 40.2 % of patients had *de novo* metastatic disease, 23.7 % had bone-only disease, and 56.7 % had visceral disease.

The study met the primary endpoint at the primary analysis conducted after 318 progression-free survival (PFS) events based on the investigator assessment using RECIST v1.1 criteria in the full analysis set (all randomised patients). The primary efficacy results were supported by PFS results based on blinded independent central radiological assessment. The median follow-up time at the time of primary PFS analysis was 19.2 months.

In the overall study population, the efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kryxana plus NSAID/tamoxifen plus goserelin compared to patients receiving placebo plus NSAID/tamoxifen plus goserelin (hazard ratio of 0.553, 95% CI: 0.441, 0.694, one-sided stratified log-rank test p-value 9.83×10^{-8}) with clinically meaningful treatment effect. Median PFS was 23.8 months (95 % CI: 19.2, NE) for Kryxana plus NSAID/tamoxifen plus goserelin treated patients and 13.0 months (95 % CI: 11.0, 16.4) for patients receiving placebo plus NSAID/tamoxifen plus goserelin.

Distribution of PFS is summarised in the Kaplan-Meier curve for PFS in Figure 2.

Figure 2 MONALEESA-7 - Kaplan-Meier plot of PFS in overall population based on investigator assessment



The results for PFS based on the blinded independent central radiological assessment of a randomly selected subset of approximately 40 % of randomised patients were supportive of the primary efficacy results based on the investigator's assessment (hazard ratio of 0.427; 95 % CI: 0.288, 0.633).

At the time of the primary PFS analysis overall survival data were not mature with 89 (13 %) of deaths (HR 0.916 [95 % CI: 0.601, 1.396]).

Overall response rate (ORR) per investigator assessment based on RECIST v1.1 was higher in the Kryxana arm (40.9 %; 95% CI: 35.6, 46.2) compared to the placebo arm (29.7 %; 95% CI: 24.8, 34.6, $p = 0.00098$). The observed clinical benefit rate (CBR) was higher in Kryxana arm (79.1 %; 95 % CI: 74.8:83.5) compared to placebo arm (69.7 %; 95 % CI: 64.8:74.6, $p = 0.002$).


In the pre-specified subgroup analysis of 495 patients who had received Kryxana or placebo in combination with NSA1 plus goserelin, the median PFS was 27.5 months (95 % CI: 19.1, NE) in the

Kryxana plus NSAID subgroup and 13.8 months (95 % CI: 12.6, 17.4) in the placebo plus NSAID subgroup [HR: 0.569; 95 % CI: 0.436, 0.743]. Efficacy results are summarised in Table 10 and the Kaplan-Meier curves for PFS are provided in Figure 3.

Table 11 MONALEESA-7 - Efficacy results (PFS) in patients who received NSAID

	Kryxana plus NSAI plus goserelin N = 248	Placebo plus NSAI plus goserelin N = 247
Progression free survival ^a		
Median PFS [months] (95 % CI)	27.5 (19.1, NE)	13.8 (12.6 – 17.4)
Hazard ratio (95 % CI)	0.569 (0.436, 0.743)	
CI=confidence interval; N=number of patients; NE = Not estimable. ^a – PFS based on investigator radiological assessment		

Figure 3 MONALEESA-7 – Kaplan-Meier plot of PFS based on investigator assessment in patients who received NSAID



Efficacy results for overall response rate (ORR) and clinical benefit rate (CBR) per investigator assessment based on RECIST v1.1 are provided in Table 12.

Table 12 MONALEESA-7 - Efficacy results (ORR, CBR) based on investigator assessment in patients who received NSAI.

Analysis	Kryxana plus NSAI plus goserelin (%, 95 % CI)	Placebo plus NSAI plus goserelin (%, 95 % CI)
Full analysis set	N = 248	N = 247
Overall response rate (ORR)^a	39.1 (33.0, 45.2)	29.1 (23.5, 34.8)
Clinical benefit rate (CBR)^b	80.2 (75.3, 85.2)	67.2 (61.4, 73.1)
Patients with measurable disease	N = 192	N = 199
Overall response rate^a	50.5 (43.4, 57.6)	36.2 (29.5, 42.9)
Clinical benefit rate^b	81.8 (76.3, 87.2)	63.8 (57.1, 70.5)
^a ORR: proportion of patients with complete response + partial response ^b CBR: proportion of patients with complete response + partial response + (stable disease or non-complete response/Non-progressive disease ≥ 24 weeks)		

Results in the Kryxana plus NSAI subgroup were consistent across subgroups of age, race, prior adjuvant/ neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease.


A more mature update of efficacy data (30 November 2018 cut off) is provided in Table 13 and Figures 4 and 5.

In the second OS analysis the study met its key secondary endpoint demonstrating a statistically significant improvement in OS.

Table 13 MONALEESA-7 – Efficacy results (OS)


	Updated analysis (30 November 2018 cut-off)	
Overall survival, overall study population	Ribociclib 600 mg N = 335	Placebo N = 337
Number of events – n [%]	83 (24.8)	109 (32.3)
Median OS [months] (95% CI)	NE (NE, NE)	40.9 (37.8, NE)
Hazard ratio (95% CI)	0.712 (0.535, 0.948)	
p-value ^a	0.00973	
Overall survival, NSAI subgroup	Ribociclib 600 mg N = 248	Placebo N = 247
Number of events – n [%]	61 (24.6)	80 (32.4)
Median OS [months] (95 % CI)	NE (NE, NE)	40.7 (37.4, NE)
Hazard ratio (95 % CI)	0.699 (0.501, 0.976)	
CI = confidence interval, NE = not estimable, N = number of patients;		
^a p-value is obtained from the one-sided log-rank test stratified by lung and/or liver metastases, prior chemotherapy for advanced disease, and endocrine partner per IRT		

Figure 4 MONALEESA-7: Kaplan Meier plot of final OS analysis (30-Nov-2018 cut-off)



Log-rank test and Cox model are stratified by lung and/or liver metastasis, prior chemotherapy for advanced disease, and endocrine combination partner per IRT

Figure 5 MONALEESA-7: Kaplan Meier plot of final OS analysis in patients who received NSAI (30-Nov-18 cut-off)



Hazard ratio is based on unstratified Cox model.

Additionally, the probability of progression on next-line therapy or death (PFS2) in patients who received prior ribociclib in the study was lower compared to patients in the placebo arm with an HR of 0.692 (95 % CI: 0.548, 0.875) in the overall study population. The median PFS2 was 32.3 months (95 % CI: 27.6, 38.3) in the placebo arm and was not reached (95 % CI: 39.4, NE) for the ribociclib arm. Similar results were observed for the NSAI subgroup, with an HR of 0.660 (95 % CI: 0.503, 0.868) and a median PFS2 of 32.3 months (95 % CI: 26.9, 38.3) in the placebo arm versus not reached (95 % CI: 39.4, NE) in the ribociclib arm.

Study CLEE011F2301 (MONALEESA-3)

Kryxana was evaluated in a randomised double-blind, placebo-controlled, multicentre phase III clinical study in 726 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who had received no or only one line of prior endocrine treatment, in combination with fulvestrant versus fulvestrant alone.

A total of 726 female patients were randomised in a 2:1 ratio to receive either Kryxana 600 mg and fulvestrant (n = 484) or placebo and fulvestrant (n = 242), stratified according to the presence of liver and/or lung metastases (Yes [n = 351 (48.3 %)] versus No [n = 375 (51.7 %)]) and according to prior endocrine therapy (A [n = 354 (48.8 %)] versus B [n=372 (51.2 %)]).

Stratum A (first-line patients with advanced breast cancer) included de novo advanced breast cancer with no prior endocrine therapy, and patients who relapsed after 12 months of (neo) adjuvant endocrine therapy completion. Stratum B (early relapse/second-line patients with advanced breast cancer) included patients whose disease relapsed during adjuvant therapy or prior to 12 months after (neo) adjuvant endocrine therapy completion, and patients who had progression after one line of endocrine therapy with either advanced breast cancer at diagnosis or relapse after 12 months of (neo) adjuvant endocrine therapy completion.

Demographics and baseline disease characteristics were balanced and comparable between study arms. Kryxana 600 mg or placebo were given orally daily for 21 consecutive days followed by 7 days off treatment in combination with fulvestrant 500 mg intramuscularly once daily on Days 1 and 15 in Cycle 1 and Day 1 of each subsequent 28-day cycle. Patients were not allowed to cross over from placebo to Kryxana during the study or after disease progression.

Patients enrolled in this study had a median age of 63 years (range 31 to 89). 46.7 % of patients were of age 65 years and older, including 13.8 % patients of age 75 years and older. The patients included were Caucasian (85.3 %), Asian (8.7 %) or Black (0.7 %) and nearly all patients (99.7%) had an

ECOG performance status of 0 or 1. First and second line patients were enrolled in this study (of whom 19.1% had *de novo* metastatic disease). Prior to study entry 42.7 % of patients had received chemotherapy in the adjuvant and 13.1 % in the neoadjuvant setting, while 58.5 % had received endocrine therapy in the adjuvant and 1.4 % in the neoadjuvant setting and 21 % had received prior endocrine therapy in the advanced breast cancer setting. In study F2301 21.2 % had bone-only disease and 60.5 % had visceral disease.

Primary analysis

The study met the primary endpoint at the primary analysis conducted after 361 progression-free survival (PFS) events based on the investigator assessment and using RECIST v1.1 criteria in the full analysis set (all randomised patients, 03 November 2017 cut-off). The median follow-up time at the time of primary PFS analysis was 20.4 months.

The primary efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kryxana plus fulvestrant compared to patients receiving placebo plus fulvestrant in the full analysis set (hazard ratio of 0.593, 95 % CI: 0.480, 0.732, one-sided stratified log-rank test p-value 4.1×10^{-7}), with an estimated 41% reduction in relative risk of progression or death in favour of the Kryxana plus fulvestrant arm.


The primary efficacy results were supported by a random central audit of 40 % imaging subset by a blinded independent central radiological assessment (hazard ratio of 0.492; 95 % CI: 0.345, 0.703).

A descriptive update of PFS was performed at the time of the second OS interim analysis, and the updated PFS results on the overall population and the subgroups based on prior endocrine therapy are summarised in Table 14 and the Kaplan-Meier curve is provided in Figure 6.

Table 14 MONALEESA 3 (F2301) Efficacy Updated results (PFS) results based on investigator radiological assessment (03-Jun-2019 cut-off)

	Kryxana plus fulvestrant N = 484	Placebo plus fulvestrant N = 242
Progression free survival overall study population		
Number of events- n [%]	283 (58.5)	193 (79.8)
Median PFS [months] (95 % CI)	20.6 (18.6, 24.0)	12.8 (10.9, 16.3)
Hazard ratio (95% CI)	0.587 (0.488, 0.705)	
First-line setting subgroup^a	Kryxana plus fulvestrant N = 237	Placebo plus fulvestrant N = 128
Number of events- n [%]	112 (47.3)	95 (74.2)
Median PFS [months] (95 % CI)	33.6 (27.1, 41.3)	19.2 (14.9, 23.6)
Hazard ratio (95% CI)	0.546 (0.415, 0.718)	
Second-line setting or early relapse subgroup^b	Kryxana plus fulvestrant n=237	Placebo plus fulvestrant n=109
Number of events- n [%]	167 (70.5)	95 (87.2)
Median PFS [months] (95 % CI)	14.6 (12.5, 18.6)	9.1 (5.8, 11.0)
Hazard ratio (95 % CI)	0.571 (0.443, 0.737)	
CI=confidence interval		
^a patients with <i>de novo</i> advanced breast cancer with no prior endocrine therapy, and patients who relapsed after 12 months of (neo)adjuvant endocrine therapy completion.		
^b patients whose disease relapsed during adjuvant therapy or within 12 months of (neo)adjuvant endocrine adjuvant therapy completion, and patients who had progression after one line of endocrine therapy for advanced disease.		

Figure 6 MONALEESA 3 (F2301) – Kaplan Meier plot of PFS based on investigator assessment (FAS) (03-Jun-2019 cut-off)



Efficacy results for overall response rate (ORR) and clinical benefit rate (CBR) per investigator assessment based on RECIST v1.1 are provided in Table 15.

Table 15 MONALEESA-3 - Efficacy results (ORR, CBR) based on investigator assessment

Analysis	Kryxana plus fulvestrant (%, 95 % CI)	Placebo plus fulvestrant (%, 95 % CI)
Full analysis set	N = 484	N = 242
Overall response rate (ORR)^a	32.4 (28.3, 36.6)	21.5 (16.3, 26.7)
Clinical benefit rate (CBR)^b	70.2 (66.2, 74.3)	62.8 (56.7, 68.9)
Patients with measurable disease	N = 379	N = 181
Overall response rate^a	40.9 (35.9, 45.8)	28.7 (22.1, 35.3)
Clinical benefit rate^b	69.4 (64.8, 74.0).	59.7 (52.5, 66.8)
^a ORR: proportion of patients with complete response + partial response		
^b CBR: proportion of patients with complete response + partial response + (stable disease or non-complete response/Non-progressive disease ≥ 24 weeks)		

Hazard ratios based on pre-specified subgroup analysis of the patients treated with Kryxana plus fulvestrant showed consistent benefit across different subgroups including age, prior treatment (early or advanced), prior adjuvant/neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease.

OS Analysis

In the second OS analysis the study met its secondary endpoint, demonstrating a statistically significant improvement in OS.

The results from this final OS analysis are provided in Table 16 and Figure 7.

Table 16 MONALEESA-3 (F2301) efficacy results (OS) (03-Jun-19 cut-off)

	Kryxana 600 mg	Placebo
Overall study population	N = 484	N = 242
Number of events - n [%]	167 (34.5)	108 (44.6)
Median OS [months] (95% CI)	NE, (NE, NE)	40 (37, NE)
HR (95% CI) ^a	0.724 (0568, 0924)	
p value ^b	0.00455	

^aHazard ratio is obtained from the Cox PH model stratified by lung and/or liver metastasis, previous endocrine therapy per interactive response technology (IRT).
NE = Not estimable

^bOne-sided P-value is obtained from log-rank test stratified by lung and/or liver metastasis, previous endocrine therapy per IRT. P-value is one-sided and is compared against a threshold of 0.01129 as determined by the Lan-DeMets (O'Brien-Fleming) alpha-spending function for an overall significance level of 0.025.

Elderly patients

No overall differences in safety or effectiveness of Kryxana were observed between elderly patients and younger patients (see section 4.2).

Paediatric population

Kryxana is not indicated for use in patients < 18 years of age

5.2 Pharmacokinetic properties

The pharmacokinetics of ribociclib were investigated in patients with advanced cancer following oral daily doses of 50 mg to 1200 mg. Healthy subjects received single oral doses ranging from 400 mg to 600 mg or repeated daily doses (8 days) at 400 mg.

Absorption

The absolute bioavailability of ribociclib is not known.

The time to reach $C_{\max}$ ($T_{\max}$) following ribociclib oral administration was between 1 and 4 hours.

Ribociclib exhibited slightly over-proportional increases in exposure ($C_{\max}$ and AUC) across the dose range tested (50 to 1200 mg). Following repeated once-daily dosing, steady state was generally achieved after 8 days and ribociclib accumulated with a geometric mean accumulation ratio of 2.51 (range: 0.97 to 6.40).

Food effect

Compared to the fasted state, oral administration of a single 600 mg dose of ribociclib film-coated tablets with a high-fat, high-calorie meal had no effect on the rate and extent of absorption of ribociclib.

Distribution

Binding of ribociclib to human plasma proteins *in vitro* was approximately 70 % and was independent of concentration (10 to 10000 ng/ml). Ribociclib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.04. The apparent volume of distribution at steady state (V_{ss}/F) was 1090 L based on population pharmacokinetic analysis.

Biotransformation

In vitro and *in vivo* studies indicated ribociclib is eliminated primarily via hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of [^{14}C] ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Phase II conjugates of ribociclib phase I metabolites involved N-acetylation, sulfation, cysteine conjugation, glycosylation and glucuronidation. Ribociclib was the major circulating drug-derived entity in plasma. The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1

(secondary glucuronide). Clinical activity (pharmacological and safety) of ribociclib was due primarily to parent drug, with negligible contribution from circulating metabolites.

Ribociclib was extensively metabolised, with unchanged drug accounting for 17.3 % and 12.1 % of the dose in faeces and urine, respectively. Metabolite LEQ803 was a significant metabolite in excreta and represented approximately 13.9 % and 3.74 % of the administered dose in faeces and urine, respectively. Numerous other metabolites were detected in both faeces and urine in minor amounts (≤ 2.78 % of the administered dose).

Elimination

The geometric mean plasma effective half-life (based on accumulation ratio) was 32.0 hours (63 % CV) and the geometric mean apparent oral clearance (CL/F) was 25.5 l/hr (66 % CV) at steady state at 600 mg in patients with advanced cancer. The geometric mean apparent plasma terminal half-life ($T_{1/2}$) of ribociclib ranged from 29.7 to 54.7 hours and the geometric mean CL/F of ribociclib ranged from 39.9 to 77.5 l/hr at 600 mg across studies in healthy subjects.

Ribociclib and its metabolites are eliminated mainly via faeces, with a small contribution of the renal route. In 6 healthy male subjects, following a single oral dose of [^{14}C] ribociclib, 91.7 % of the total administered radioactive dose was recovered within 22 days; faeces was the major route of excretion (69.1 %), with 22.6 % of the dose recovered in urine.

Linearity/non-linearity

Ribociclib exhibited slightly over-proportional increases in exposure (C_{max} and AUC) across the dose range of 50 mg to 1200 mg following both single dose and repeated doses.

Special populations

Renal impairment

Based on a population pharmacokinetic analysis that included 77 patients with normal renal function ($\text{eGFR} \geq 90 \text{ ml/min/1.73 m}^2$), 76 patients with mild renal impairment ($\text{eGFR} 60 \text{ to } < 90 \text{ ml/min/1.73 m}^2$) and 35 patients with moderate renal impairment ($\text{eGFR} 30 \text{ to } < 60 \text{ ml/min/1.73 m}^2$), mild and moderate renal impairment had no effect on the exposure of ribociclib (see section 4.2). The pharmacokinetics of ribociclib in patients with severe renal impairment have not been studied.

Hepatic impairment

Based on a pharmacokinetic study in patients with hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib (see section 4.2). The mean exposure for ribociclib was increased less than 2-fold in patients with moderate (geometric mean ratio [GMR]: 1.50 for C_{max} ; 1.32 for AUC_{inf}) and severe (GMR: 1.34 for C_{max} ; 1.29 for AUC_{inf}) hepatic impairment. Based on a population pharmacokinetic analysis that included 160 breast cancer patients with normal hepatic function and 47 patients with mild hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib, further supporting the findings from the dedicated hepatic impairment study (see section 4.2).

Effect of age, weight, gender and race

Population pharmacokinetic analysis showed that there are no clinically relevant effects of age, body weight or gender on the systemic exposure of ribociclib that would require a dose adjustment. Data on differences in pharmacokinetics due to race are too limited to draw conclusions.

In vitro interaction data

Effect of ribociclib on cytochrome P450 enzymes

In vitro, ribociclib is a reversible inhibitor of CYP1A2, CYP2E1 and CYP3A4/5 and a time-dependent inhibitor of CYP3A4/5, at clinically relevant concentrations. *In vitro* evaluations indicated that ribociclib has no potential to inhibit the activities of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at clinically relevant concentrations. Ribociclib has no potential for time-dependent inhibition of CYP1A2, CYP2C9, and CYP2D6.

In vitro data indicate that ribociclib has no potential to induce UGT enzymes or the CYP enzymes CYP2C9, CYP2C19 and CYP3A4 via PXR. Therefore, Kryxana is unlikely to affect substrates of these enzymes. *In vitro* data are not sufficient to exclude a potential of ribociclib to induce CYP2B6 via CAR.

Effect of transporters on ribociclib

Ribociclib is a substrate for P-gp *in vitro*, but based on mass balance data inhibition of P-gp or BCRP is unlikely to affect ribociclib exposure at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1, OATP1B3 or OCT-1 *in vitro*.

Effect of ribociclib on transporters

In vitro evaluations indicated that ribociclib has a potential to inhibit the activities of drug transporters P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP. Ribociclib did not inhibit OAT1, OAT3 or MRP2 at clinically relevant concentrations *in vitro*.

5.3 Preclinical safety data

Safety pharmacology

In vivo cardiac safety studies in dogs demonstrated dose and concentration related QTc interval

prolongation at an exposure that would be expected to be achieved in patients following the recommended dose of 600 mg. There is also potential to induce incidences of premature ventricular contractions (PVCs) at elevated exposures (approximately 5-fold the anticipated clinical C_{max}).

Repeated-dose toxicity

Repeated-dose toxicity studies (treatment schedule of 3 weeks on/1 week off) of up to 27 weeks' duration in rats and up to 39 weeks' duration in dogs, revealed the hepatobiliary system (proliferative changes, cholestasis, sand-like gallbladder calculi, and inspissated bile) as the primary target organ of toxicity of ribociclib. Target organs associated with the pharmacological action of ribociclib in repeat-dose studies include bone marrow (hypocellularity), lymphoid system (lymphoid depletion), intestinal mucosa (atrophy), skin (atrophy), bone (decreased bone formation), kidney (concurrent degeneration and regeneration of tubular epithelial cells) and testes (atrophy). Besides the atrophic changes seen in the testes, which showed a trend towards reversibility, all other changes were fully reversible after a 4-week treatment-free period. Exposure to ribociclib in animals in the toxicity studies was generally less than or equal to that observed in patients receiving multiple doses of 600 mg/day (based on AUC).

Reproductive toxicity/Fertility

Ribociclib showed **foetotoxicity** and **teratogenicity** at doses which did not show maternal toxicity in the rats or rabbits. Following prenatal exposure, increased incidences of post-implantation loss and reduced foetal weights were observed in rats and ribociclib was teratogenic in rabbits at exposures lower than or 1.5 times the exposure in humans, respectively, at the highest recommended dose of 600 mg/day based on AUC.

In rats, reduced foetal weights accompanied by skeletal changes considered to be transitory and/or related to the lower foetal weights were noted. In rabbits, there were adverse effects on embryo-foetal development as evidenced by increased incidences of foetal abnormalities (malformations and

external, visceral and skeletal variants) and foetal growth (lower foetal weights). These findings included reduced/small lung lobes and additional vessel on the aortic arch and diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes and reduced/small accessory lung lobe (30 and 60 mg/kg), extra/rudimentary thirteenth ribs and misshapen hyoid bone and reduced number of phalanges in the pollex. There was no evidence of embryo-foetal mortality.

In a fertility study in female rats, ribociclib did not affect reproductive function, fertility or early embryonic development at any dose up to 300 mg/kg/day (which is likely at an exposure lower than or equal to patients' clinical exposure at the highest recommended dose of 600 mg/day based on AUC).

Ribociclib has not been evaluated in male fertility studies. However, atrophic changes in testes were reported in rat and dog toxicity studies at exposures that were less than or equal to human exposure at the highest recommended daily dose of 600 mg/day based on AUC. These effects can be linked to a direct anti-proliferative effects on the testicular germ cells resulting in atrophy of the seminiferous tubules.

Ribociclib and its metabolites passed readily into rat milk. The exposure to ribociclib was higher in milk than in plasma.

Genotoxicity

Genotoxicity studies in bacterial *in vitro* systems and in mammalian *in vitro* and *in vivo* systems with and without metabolic activation did not reveal any evidence for a genotoxic potential of ribociclib.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients.

Tablet core

Microcrystalline cellulose

Crospovidone type A

Low-substituted hydroxypropylcellulose

Magnesium stearate

Colloidal anhydrous silica

Film coating

Iron oxide black (E172)

Iron oxide red (E172)

Soya lecithin (E322)

Polyvinyl alcohol (partially hydrolysed)

Talc

Titanium dioxide (E171)

Xanthan gum

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Store at or below 30 °C, 3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene) or PA/alu/PVC

(polyamide/aluminium/polyvinylchloride) blisters containing 14 or 21 film-coated tablets.

Unit packs containing 21, 42 or 63 film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis South Africa (Pty) Ltd.

Magwa Crescent West

Waterfall City, Jukskei View

Johannesburg

2090

8. MARKETING AUTHORISATION NUMBER(S)

52/26/0356

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

21 April 2020

10. DATE OF REVISION OF THE TEXT

21 July 2022

2018-PSB/GLC-0935-s
2019-PSB/GLC-1085-e